Cargando…
Orphan drugs: Unmet societal need for non-profitable privately supplied new products
Due to the severity of rare diseases, the societal need for biopharmaceutical treatments for these diseases is high, despite low numbers of patients. Therefore, we investigated the barriers currently hindering the willingness to develop orphan drugs in the Netherlands. To this end, a robust, small s...
Autores principales: | Moors, Ellen H.M., Faber, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112095/ http://dx.doi.org/10.1016/j.respol.2006.12.006 |
Ejemplares similares
-
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
por: Brabers, Anne EM, et al.
Publicado: (2011) -
Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
por: Desser, Arna S, et al.
Publicado: (2010) -
The differential impacts of PEPFAR transition on private for-profit, private not-for-profit and publicly owned health facilities in Uganda
por: Wilhelm, Jess Alan, et al.
Publicado: (2020) -
Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021) -
Societal preferences for funding orphan drugs in China: An application of the discrete choice experiment method
por: Tan, Shuoyuan, et al.
Publicado: (2022)